BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30917458)

  • 1. [PD-L1 expression is related with prognosis of small cell lung cancer].
    Qiu YJ; Zhang MZ
    Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):214-217. PubMed ID: 30917458
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
    Kato Y; Kashima J; Watanabe K; Yomota M; Zenke Y; Okuma Y; Hosomi Y; Gemma A; Seike M; Okamura T
    Anticancer Res; 2018 Feb; 38(2):1077-1083. PubMed ID: 29374744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
    Yoshimura A; Yamada T; Miyagawa-Hayashino A; Sonobe Y; Imabayashi T; Yamada T; Okada S; Shimamoto T; Chihara Y; Iwasaku M; Kaneko Y; Uchino J; Inoue M; Konishi E; Takayama K
    Lung Cancer; 2019 Nov; 137():108-112. PubMed ID: 31568887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
    Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
    Guleria P; Kumar S; Malik PS; Jain D
    Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
    Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
    Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters.
    Sudha S; Shukla S; Husain N; Kumar H; Pandey RK; Kant S
    Pol J Pathol; 2024; 75(1):25-35. PubMed ID: 38808606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
    Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
    Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
    Vrankar M; Zwitter M; Kern I; Stanic K
    Neoplasma; 2018; 65(1):140-146. PubMed ID: 29322798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
    Imanishi N; Hirai A; Yoneda K; Shimajiri S; Kuwata T; Tashima Y; Takeuchi M; Iwai Y; Ichiki Y; Tanaka F
    J Surg Oncol; 2018 Jun; 117(7):1563-1569. PubMed ID: 29601633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.